Crinetics PharmaceuticalsCRNX -0.04%41 Gross Margin % is 98.14% as of Mar. 2026, which is 14% above its 10-year median of 86.02. GuruFocus rates CRNX with a GF Score™ of 41/100 and a GF Value™ of $724.66 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 729 Biotechnology companies, Crinetics Pharmaceuticals ranks better than 96.3% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Crinetics Pharmaceuticals had a gross margin of 98.14% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Crinetics Pharmaceuticals Gross Margin % Related Terms
Crinetics Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRNX vs CPRX, NAMS, RCUS: Gross Margin % Comparison
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Crinetics Pharmaceuticals (CRNX) has a Gross Margin % of 98.14% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Crinetics Pharmaceuticals and its competitors. This is 14% above median its historical median of 86.02. Over the past decade, Crinetics Pharmaceuticals' Gross Margin % has ranged from 86.02 to 98.89. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #27 out of 729 companies in the Biotechnology industry, placing it in the top 3.7%.
Is Crinetics Pharmaceuticals' Gross Margin % too high?
Crinetics Pharmaceuticals' current Gross Margin % of 98.14% is 14% above median its 10-year median of 86.02. Over the past 10 years, this metric has ranged from a low of 86.02 to a high of 98.89. The Biotechnology industry median Gross Margin % is 60.92. Crinetics Pharmaceuticals' value of 98.14% is 61.1% above this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #27 out of 729 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Gross Margin % compare to CPRX and NAMS?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #27 out of 729 companies for Gross Margin %. This places Crinetics Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Crinetics Pharmaceuticals' value of 98.14% is 61.1% above this benchmark. Historically, Crinetics Pharmaceuticals' own Gross Margin % has ranged from 86.02 to 98.89 over the past decade. While the company's 10-year median is 86.02 vs. the industry median of 60.92, Crinetics Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Gross Margin % of 98.14% is 61.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Gross Margin % is 98.14%, which is 14% above median its own 10-year median of 86.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (CRNX) is currently considered Possible Value Trap. The stock's GF Value™ is $724.66, compared to a current price of $83.45 — trading 88.5% below its estimated fair value. The current Gross Margin % is 98.14%, which is 14% above median its 10-year median of 86.02 and 61.1% above the Biotechnology industry median of 60.92. Crinetics Pharmaceuticals' overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Crinetics Pharmaceuticals (CRNX), the current Gross Margin % is 98.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of $83.45 is trading 88.5% below its estimated GF Value™ of $724.66.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CRNX:
Gross Margin %: 98.14% (14% above median its 10-year median of 86.02)
GF Value™: $724.66 vs. price of $83.45 (88.5% below fair value)
Industry Position: 61.1% above the Biotechnology median (#27 of 729)
No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
41GF Score
Get the complete analysis for CRNX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRNX has been successfully added to your 
